Cardiomyopathy caused by lamin A/C gene (LMNA) mutations (hereafter referred as LMNA cardiomyopathy) is characterized by cardiac conduction abnormalities and left ventricular systolic dysfunction predisposing to heart failure. Previous cardiac transcriptional profiling of Lmna H222P/H222P mouse, a small animal model of LMNA cardiomyopathy, suggested decreased WNT/b-catenin signalling. We confirmed decreased WNT/b-catenin signalling in the hearts of these mice by demonstrating decreased b-catenin and WNT proteins. This was correlated with increased expression of soluble Frizzled-related proteins that modulate the WNT/b-catenin signalling pathway. Hearts of Lmna H222P/H222P mice also demonstrated lowered expression of the gap junction connexin 43. Activation of WNT/b-catenin activity with 6-bromoindirubin-3'-oxime improved cardiac contractility and ameliorated intraventricular conduction defects in Lmna H222P/H222P mice, which was associated with increased expression of myocardial connexin 43. These results indicate that decreased WNT/b-catenin contributes to the pathophysiology of LMNA cardiomyopathy and that drugs activating b-catenin may be beneficial in affected individuals.
Introduction
Dominant mutations in the lamin A/C gene (LMNA), which encodes A-type nuclear lamins, cause dilated cardiomyopathy (herein referred to as LMNA cardiomyopathy), often associated with skeletal myopathy such as Emery-Dreifuss muscular dystrophy (1, 2) . LMNA cardiomyopathy is characterized by early conduction defects, impaired myocardial contractility and ventricular dilation, eventually causing heart failure (3) (4) (5) . It has a more aggressive course than other inherited dilated cardiomyopathies due to the high incidence of heart block and ventricular arrhythmias (5) . While sudden death from arrhythmias may be prevented by implantation of a pacemaker and/or defibrillator, the progressive heart failure eventually becomes resistant to treatment and heart transplantation is often the only therapeutic option (4) .
To decipher mechanistic events underlying the pathogenesis of LMNA cardiomyopathy, we have studied Lmna mice, which recapitulate the cardiac pathology that occurs in human subjects. These mice develop left ventricular dilatation and conduction defects in adulthood (6) . Despite normal heart histology and the absence of left ventricular dilatation at early ages, cardiac transcriptional profiling has identified alterations in several cellular signalling pathways, including WNT/bcatenin (7, 8) .
WNT proteins are a family of secreted cysteine-rich glycoproteins implicated in a variety of cellular processes, including proliferation, differentiation, apoptosis, polarity, and senescence (9, 10) . There are 19 human WNT genes, which encode proteins that have been grouped into two classes: those in the canonical and non-canonical WNT pathways. In the canonical WNT signalling cascade, the expression level of b-catenin, the key effector functioning as a transcriptional co-activator, is critical for target gene expression. In the absence of WNT ligand, b-catenin is captured by the scaffold protein Axin, which facilitates its phosphorylation by glycogen synthase kinase 3-b (GSK3-b) in a destruction complex. E3-ubiquitin ligase b-TrCP then catalyzes the ubiquitination of phosphorylated b-catenin, which is subsequently rapidly degraded by the proteasome. Upon WNT ligand binding to the Frizzled and low-density lipoprotein receptor 5/6 complex, the b-catenin destruction complex becomes dysfunctional by a mechanism that is not fully understood. As a result, the newly synthesized b-catenin accumulates in the cytosol, translocates to the nucleus and forms a complex with transcription factor TCF/LEF, leading to activation of target genes.
Frizzled-related proteins and Dickkopfs are modulators of WNT/b-catenin signalling. These proteins have been shown to play a role in various cardiac pathophysiological processes (11) (12) (13) . Given the alterations of WNT/b-catenin signalling in hearts of Lmna H222P/H222P mice suggested by transcriptional profiling (7, 8) , we explored the potential involvement of this pathway in the pathophysiology of LMNA cardiomyopathy.
Results
The canonical WNT/b-catenin signalling pathway is impaired in LMNA cardiomyopathy mice. Immunoblotting of heart lysates from 3 month-old and 6 month-old Lmna H222P/H222P mice demonstrated a decrease in both total and active forms of b-catenin compared to wild type mice (Fig. 1A) . Given that b-catenin expression was lowered in hearts from Lmna H222P/H222P mice, we next assessed the canonical WNT/b-catenin signalling activity. We observed significantly decreased expression of WNT1, and WNT10b in hearts from 6 month-old Lmna H222P/H222P mice compared to wild type mice (Fig. 1B) . We next showed that b-catenin expression was significantly lowered in isolated cardiomyocytes from 6-month old Lmna H222P/H222P mice compared to wild type mice (Fig. 1C) . We also analysed left ventricle tissue from three human subjects with LMNA cardiomyopathy obtained after cardiac transplantation. Immunoblotting using antibody against total b-catenin showed decreases in this protein in heart tissue of the patients with LMNA mutations compared with controls ( Fig. 1D) Fig. 2A) . We confirmed that the expression of sFRP1 protein was increased in hearts from 6-month old Lmna H222P/H222P mice compared to wild type mice (Fig. 2B ). The expression of Dkk3 protein was similarly increased in heart tissues from subjects with LMNA cardiomyopathy (Fig.  2C ). These data suggested that activation of extracellular inhibitors could trigger the inhibition of cardiac WNT/b-catenin signalling in LMNA cardiomyopathy.
Altered gap junction structure in LMNA cardiomyopathy b-catenin is also located in intercalated discs (ICD). This cellular junction is a tightly regulated part of cardiomyocytes and composed of desmosomes, adherens junctions and gap junctions. Therefore, we assessed the architecture of ICDs in Lmna H222P/H222P mice. Immunofluorescence microscopic analyses of specific junctional components were performed on sections of heart tissue from 3 month-old mice as well as in isolated cardiomyocytes. The localization of b-catenin, a component of adherens junctions, was not altered in Lmna H222P/H222P mice compared to wild type mice (Fig. 3A) .
Similarly, the localization of N-cadherin, a component of both adherens junction and desmosomes, was not altered in Lmna H222P/H222P mice (Fig. 3B) Activating WNT/b-catenin signalling improves cardiac function in LMNA H222P/H222P mice Given the altered WNT/b-catenin signalling in hearts of Lmna H222P/H222P mice, we hypothesized that increasing this pathway's activity would prevent the progression of left ventricular dysfunction and conduction defects. We therefore treated male Lmna H222P/H222P mice with daily intra-peritoneal injections of 1.25 lg/kg/day of 6-bromoindirubin-3'-oxime (BIO) (Fig. 4A ). BIO is a highly potent, selective ATP-competitive inhibitor of GSK3-b that activates the WNT/b-catenin signalling (15) . After 1 month of treatment starting at 4 months of age, Lmna H222P/H222P mice were analysed using echocardiography and electrocardiography and then sacrificed for biochemical and histological analyses. BIO treatment increased GSK3-b phosphorylation (inactive form) and total b-catenin in hearts of Lmna H222P/H222P mice compared to dimethyl sulfoxide (DMSO) placebo treatment (Fig. 4B ). This demonstrated that BIO positively regulated WNT/b-catenin signalling. M-mode echocardiography showed that left ventricular end-diastolic and endsystolic diameters in Lmna H222P/H222P mice treated with BIO were significantly smaller and fractional shortening was significantly increased compared to placebo-treated mice ( Fig. 4C ; Table 1 ).
Treating Lmna H222P/H222P mice with BIO also lead to a significant reduction of mRNA levels of NppA and NppB, genes that encode natriuretic peptide precursors that are markers for heart failure, The QRS interval represents the time taken for the excitatory impulse to propagate throughout the ventricles, which is partly determined by the resistance of the intercellular connections between myocytes (16). Decreased expression of connexin 43 is associated with intraventricular conduction slowing and QRS prolongation (17) (18) (19) . BIO treatment of Lmna H222P/H222P mice lead to increased expression of cardiac connexin 43, which occurs in parallel with re-expression b-catenin and WNT-1 (Fig. 5A) . We confirmed this re-expression of connexin 43 by immunohistochemistry on heart from BIO-treated Lmna H222P/H222P mice compared to DMSO-treated mice (Fig. 5B) . Given that correct localization of connexin 43 at gap junctions is important for myocyte-myocyte junctions and functions, we hypothesized that BIO treatment improves intraventricular conduction by normalizing expression of connexin 43 in hearts of Lmna LGK974, which inhibit WNT/b-catenin signalling, showed decreased connexin 43 expression compared to DMSO-treated cells (Fig. 5D ). These results demonstrated that WNT/b-catenin signalling triggers the expression of connexin 43, which is expressed at abnormally low levels in LMNA cardiomyopathy.
Discussion
Our findings suggest a physiological role for A-type lamins as a modifier of WNT/b-catenin signalling in the heart. This is consistent with work from Hernandez and colleagues that showed deficient WNT/b-catenin signalling activity in Lmna
mice (20) , a small animal model for premature ageing with cardiac defects (21) . Some evidence suggests that WNT/b-catenin signalling is regulated by emerin, another protein of the inner nuclear membrane, which interacts with A-type lamins (22) (23) (24) . Mutations in EMD, the gene encoding emerin, also cause dilated cardiomyopathy (25) . and nesprins may form a complex that modulates, at least to some extent, similar cellular signalling pathways that are involved in the pathogenesis of dilated cardiomyopathy. Activation of WNT/b-catenin signalling has been reported to be involved in cardiac hypertrophy (30) . There is increasing evidence that WNT/b-catenin signalling is also involved in cardiac remodelling and the progression to heart failure. We observed an up-regulation of soluble modulators of WNT/b-catenin signalling in hearts of Lmna H222P/H222P mice and human subjects with LMNA cardiomyopathy. Enhanced expression of Frizzled transcripts has been reported in several heart diseases and cardiomyopathies (30) . Therefore, we can speculate that the upregulation of soluble modulators of WNT/b-catenin signalling could be a consequence of molecular defects leading to cardiomyopathy and heart failure, with no specificity to LMNA cardiomyopathy. The mRNA levels of sFRP3 and sFRP4 are elevated in failing ventricles compared with control donor hearts (29) . However, this finding contradicts other work showing that there is a decreased level of sFRPs in heart in an animal model of cardiac failure and in human cardiomyopathies (31) . Accordingly, administration of sFRP2 improves cardiac function in a rat model of myocardial infarction (32) . Similarly, overexpression of sFRP1 improves infarct healing and cardiac function in mice (11) . This effect appears to occur by altering type I procollagen processing by inhibiting bone morphogenic protein 1 in primary cardiac fibroblasts and therefore reducing fibrosis. Our observation showing Dkk3 overexpression in hearts from Lmna H222P/H222P mice is in contrast to other published work showing that Dkk3 attenuated pressure overload-induced cardiac remodelling (12) and protected against cardiac dysfunction and ventricular remodelling following myocardial infarction (13) . However, the pathogenic processes leading to cardiac dysfunction after infarction and in primary cardiomyopathies are likely to be very different. modulation of gap junction channel activity. In response to WNT signalling, b-catenin interacts with the gene encoding connexin 43 to increase its transcription and also appears to interact with connexin 43, likely as part of a complex with the ICD (33) . Whether this interaction is direct or requires other components of cell junctions remains to be determined. Several groups have documented downregulation or abnormal localization of connexins in experimental and human cardiomyopathies (34, 35) . This process, referred to as gap junction remodelling, is thought to predispose to cardiac conduction alterations. The robust response of connexin 43 expression to WNT/b-catenin signalling (33, 36, 37) suggests that alteration in WNT/b-catenin signalling might influence gap junction channel gene expression in the heart. This is supported by recent data showing that LRP6 deficiency disrupts gap junction formation and function (38) . Our results showing a concordant decrease in b-catenin and connexin 43 levels in hearts from Lmna H222P/H222P mice are consistent with this hypothesis. We have shown that the pharmacological activation of WNT/b-catenin signalling using a GSK3-b inhibitor induces connexin 43 expression and improves left ventricular dysfunction in Lmna H222P/H222P mice. Identified in the late 1970s as a protein kinase that inactivates glycogen synthase, GSK3 became a drug target when its role in insulin signal transduction and its potential importance for Alzheimer disease started to emerge (39) . Several potent inhibitors of GSK3 have been identified with therapeutic potential (40) . However, long-term use of GSK3 inhibitors may have potential problems. GSK3 inhibitors might be expected to mimic the WNT/b-catenin signalling and therefore could be potentially carcinogenic (41) . Nonetheless, lithium, which is a potent GSK3 inhibitors, have been used to treat bipolar disorder, and their long-term use is not known to be associated with an increased risk of cancer (42) . Careful adjustment of WNT/b-catenin signalling activity in LMNA cardiomyopathy using small molecule activators might therefore have beneficial effects in humans with LMNA cardiomyopathy. We have previously shown that pharmacological blockade of other signalling cascades -ERK1/2 (43-45), AKT/mTOR (46), TGF-b (47), CTGF (47), JNK (48), p38a (8) -also has beneficial effects on left ventricular function in Lmna H222P/H222P mice. Future studies could be designed to assess the therapeutic benefit of blocking combinations of these signalling pathways in LMNA cardiomyopathy.
Materials and Methods

Mice
Lmna H222P/H222P mice were bred and genotyped as previously described. Mice were fed chow and housed in a disease-free barrier facility with 12h/12h light/dark cycles. The Institutional Animal Care and Use Committee at Columbia University Medical Center approved the use of animals and the study protocols. 
Isolation of mouse cardiomyocytes
Human tissue samples
Sections of explanted hearts from human subjects with LMNA mutations were obtained from Myobank-AFM of l'lnstitut de Myologie. The subjects were a 23 year-old man with cardiomyopathy associated with muscular dystrophy and LMNA delK61 mutation, a 47 year-old woman with cardiomyopathy and LMNA R60G mutation and from a 62 year-old woman with cardiomyopathy associated with muscular dystrophy and LMNA c.IVS9 þ 1g sup a mutation. Control human heart samples were obtained from the National Disease Research Interchange from a 57 year-old man with an intracranial bleed and a 15 year-old woman who died of a drug overdose. All tissue samples were obtained with appropriate approvals and consent from l'lnstitut de Myologie and the National Disease Research Interchange and provided without patient identifiers.
Cell culture and reagents
C2C12 mouse myoblasts (ATCC) were maintained in DMEM supplemented with 10% Fetal Bovine Serum. Cells were incubated with BIO (10 lM) for 24 h, IWP2 (20 lM) for 24 h and LGK974 (8 lM) for 24 h.
Quantitative real-time RT-PCR analysis
Total RNA was extracted (Rneasy isolation kit, Qiagen) and cDNA was synthesized using Superscript first strand synthesis system according to the manufacturer's instructions (Invitrogen). For each replicate in each experiment, RNA from tissue samples of different animals was used. Primers were designed corresponding to mouse RNA sequences using Primer3 (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www. cgi). Real-time quantitative RT-PCR reactions contained HotStart-IT SYBR green qPCR Master Mix (Affymetrix), 200 nM of each primer and 0.2 ml of template in a 25 ml reaction volume. Amplification was carried out using the ABI 7300 Real-Time PCR System (Applied Biosystems). Relative levels of mRNA expression were calculated using the DDC T method. Individual expression values were normalized by comparison to Gapdh mRNA.
Protein extraction and immunoblotting
Human or mouse heart tissue was homogenized in sample extraction buffer (Cell Signalling) as previously described (8 
Immunofluorescence microscopy
Immunohistochemistry
Sections of heart tissue were fixed (24 h, 4% paraformaldehyde in PBS, pH 7.4 at 4 C), dehydrated (EtOH 80%, 95%, and 100%, sequentially), embedded in paraffin and sectioned at 5 lm. Sections were incubated with primary antibodies against mouse anti-connexin 43 (No ab11370, Abcam).
Mouse treatment protocols
BIO was dissolved in DMSO and delivered at doses of 1.25, 2.5 or 5 lg/kg, daily. BIO and DMSO were administered by intraperitoneal injections starting when the mice were 16 weeks of age and continued until 20 weeks of age.
Thansthoracic echocardiography
Mice were anaesthetized with 1.5% isoflurane in O 2 and placed on a heating pad (37 C). Echocardiography was performed using a Visualsonics Vevo 770 ultrasound with a 30 MHz transducer applied to the chest wall. Cardiac ventricular dimensions and fractional shortening were measured in 2D mode and M-mode 3 times for the number of animals indicated.
Electrocardiography
Electrocardiograms were recorded from mice sedated with low-dose inhaled isoflurane using the standard four limb leads and a B08 amplifier (Emka Technologies) with minimal filtering. Waveforms were recorded using Iox Software v1.8.9.18 and intervals were measured manually with ECG Auto v1.5.12.50, using the average of three representative consecutive beats. The electrocardiographer was blinded to mouse genotype.
Statistics
Values for real-time quantitative RT-PCR were compared using an unpaired Student t-test. Comparisons of echocardiographic parameters between BIO-treated and DMSO-treated Lmna H222P/H222P mice were performed using a Welch t-test; to validate these results, a non-parametric test (Mann-Whitney) was performed and concordance checked. Statistical analyses were performed using GraphPad Prism software.
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